The Medical Futurist
JUNE 17, 2025
Researchers in 2019 developed a machine learning method to accurately quantify immune cells in the vicinity of oral cancer cells. Its importance was also highlighted during the COVID-19 crisis to bypass supply chains to meet hospitals’ demands. This can lead to earlier cancer detection and more targeted treatment.
FDA Law Blog
JUNE 3, 2021
Schlanger — While federal efforts to address prescription drug prices are debated, states have continued to pursue their own measures that require drug manufacturers and other entities in the drug supply chain to disclose information about pricing. See our previous coverage of such state laws here , here and here.)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
MARCH 1, 2023
FDA published two Federal Register Notices in October 2020 to recruit domestic drug product manufacturers of finished dosage forms and foreign manufacturers of active pharmaceutical ingredients to participate in the QMM Pilot Programs. FDA describes the QMM as “above-the-bar behaviors” that exceed good manufacturing practices (GMPs).
FDA Law Blog
NOVEMBER 22, 2022
Reported illnesses began just three days before Thanksgiving in 2017, but due to the unknown source of the turkey at the center of the outbreak, the Centers for Disease Control and Prevention (CDC) did not conclude the outbreak investigation until April 2019. Two days before Thanksgiving the following year, the CDC warned U.S. 20, 2026.
FDA Law Blog
SEPTEMBER 13, 2021
A final OIG rule to change the structure of manufacturer rebates to Medicare Part D and Medicaid Managed Care plans and their PBMs is enmeshed in litigation and is likely to be at least postponed until 2026 (see our post ), and perhaps prevented from implementation altogether, by Congressional mandate.
Expert insights. Personalized for you.
126 
Let's personalize your content